ArticleFrontiers in public health2021
Molecular Epidemiology and Drug Resistant Mechanism of Carbapenem-Resistant
Article in Frontiers in public health, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 30 citations in OpenAlex.
- Enhancing the Antibacterial Activity of Endolysin againstJournal of microbiology and biotechnology · 2026Article
- Phenotype and molecular characterization of K1-ST700 hypervirulent Klebsiella pneumoniae isolated from bone marrow aspirate of a patient with multi-system infection.BMC microbiology · 2026Article
- Drug resistance mechanisms and molecular epidemiology of carbapenem-resistant Klebsiella pneumoniae in pulmonary infections.BMC infectious diseases · 2026Article
- A Pilot Study ofDiagnostics (Basel, Switzerland) · 2026Article
- Phenotypic and molecular characterization of K64 putative hypervirulent carbapenem-resistant Klebsiella pneumoniae.PloS one · 2026Article
- Hospital-Based Genomic Surveillance ofBiology · 2025Article
- Coexistence of carbapenem resistance and hypervirulence in clinical Klebsiella pneumoniae isolates: a molecular and phenotypic analysis.BMC infectious diseases · 2025Article
- Molecular Epidemiological Characteristics ofInfection and drug resistance · 2025Article
- MOLECULAR CHARACTERIZATION AND DETECTION OF MULTIDRUGRESISTANT GENE IN BACTERIAL ISOLATES CAUSING LOWER RESPIRATORY TRACT INFECTIONS (LRTI) AMONG HIV/AIDS PATIENTS ON HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART) IN UYO, SOUTH-SOUTH NIGERIA.Annals of Ibadan postgraduate medicine · 2024Article
- A Decade-Long Review of the Virulence, Resistance, and Epidemiological Risks ofMicroorganisms · 2024Review
- Article
- Virulence Factors inIndian journal of microbiology · 2024Review
- The Global and Regional Prevalence of Hospital-Acquired Carbapenem-ResistantOpen forum infectious diseases · 2024Review
- Study of the Epidemiological and Mechanistic Differences Between Carbapenem-ResistantInfection and drug resistance · 2024Article
- Occurrence of some common carbapenemase genes in carbapenem-resistant Klebsiella pneumoniae isolates collected from clinical samples in Tabriz, northwestern Iran.BMC research notes · 2023Article
- Genetic Characterization of Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2023Article
- Characterization of ST11 and ST15 Carbapenem-Resistant HypervirulentInfection and drug resistance · 2023Article
- Risk model and validation of carbapenem-resistantOpen medicine (Warsaw, Poland) · 2023Article
- Rapid ResaCeftazidime-AvibactamJournal of clinical microbiology · 2022Article
- Molecular Epidemiology and Risk Factors of Carbapenem-Resistant Klebsiella Pneumoniae Bloodstream Infections in Wuhan, China.Current medical science · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Infection by carbapenem-resistant
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.